Chronic Graft-versus-host-disease
Conditions
Brief summary
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).
Detailed description
Anlotinib 8mg qd po for 6months if no progression in 4weeks or reach PR in 3months
Interventions
DRUGAnlotinib
anlotinib 8mg qd po
Sponsors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic stem cells transplantation. 2. Steroid dependent or refractory classic chronic GVHD disease defined as modified National Institutes of Health criteria(2014) below at any time post-hematopoietic cell transplant(post-HCT) 1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to(\<=) 0.25mg/kg/day or \<=0.5mg/kg every other day(prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion 2. Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regime containing glucocorticoid (prednisolone at \>=1mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at \>=0.5mg/kg/day or 1mg/kg every other day) for at least 4 weeks. 3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting anlotinib. 4. At the time of trial enrollment, participants may be receiving other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting anlotinib. 5. Neutrophil≥1.5×109/L，platelet≥50×109/L 6. Karnofsky or Lansky performance status\>=60 7. Participants should sign the agreement.
Exclusion criteria
1. Known or suspected active acute GVHD. 2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer chemotherapy in the 4weeks prior to starting study drug. 3. Concomitant use of warfarin or other Vitamin K antogonists. 4. Known bleeding disorders or hemophilia. 5. Known history of human immunodeficiency virus or active with hepatitis C. virus or hepatitis B virus. 6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicine or recent infection requiring systemic treatment .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate as the percentage of participants with response. | 1year | Overall response rate is defined as the proportion of subjects who achieved complete response CR or partial response PR. Response criteria are based on NIH cGVHD Response assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | 1year | DOR is defined as the duration of time from the date of initial response |
Countries
China
Outcome results
None listed